In vitro studies with an ALK inhibitor, WHI-P154, and a Ba/F3 cell line model led Dr. Mano’s team to propose that ALK could be a therapeutic target in ALK-positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.